Lonafarnib is under clinical development by Eiger BioPharmaceuticals and currently in Phase III for Hepatitis D. According to GlobalData, Phase III drugs for Hepatitis D does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lonafarnib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eiger BioPharmaceuticals overview
Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company also offers post-bariatric hypoglycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.
For a complete picture of Lonafarnib’s drug-specific PTSR and LoA scores, buy the report here.